Safety and Efficacy of APG-157 in Head and Neck Cancer
Status:
Not yet recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this clinical research study is to study safety and efficacy of orally
administered APG-157 as the neoadjuvant/induction therapy in newly diagnosed, locally
advanced patients with Head & Neck Cancer of oral cavity and/or oropharynx.
The study hypothesis is that neoadjuvant use of APG-157 will reduce the tumor burden prior to
any definitive therapy to improve the outcomes over current standard of care.